Neomicina Labesfal (Neomycin)

Neomycin, the active ingredient in Neomicina Labesfal, is an aminoglycoside antibiotic presented as an oral formulation for systemic use. Originating from the European Union market, it targets intestinal infections caused by susceptible Gram‑negative and some Gram‑positive bacteria, and is used in both adult and pediatric patients requiring localized gut activity.

GNH USA supplies Neomicina Labesfal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality, regulatory adherence, and reliable and timely distribution across multiple markets.

Neomicina Labesfal (neomycin) is an aminoglycoside antibiotic used to manage bacterial infections of the gastrointestinal tract.

Intestinal bacterial infection: eradicates susceptible pathogens causing diarrhea and abdominal discomfort. Pre‑operative bowel decontamination: reduces colonic bacterial load before abdominal or colorectal surgery. Hepatic encephalopathy prophylaxis: lowers ammonia‑producing gut flora to help prevent neuro‑cognitive episodes.

Neomicina Labesfal may cause a range of adverse reactions, most of which are dose‑related and reversible upon discontinuation.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Vomiting: occasional emesis after oral intake. - Diarrhea: loose stools during therapy. - Abdominal pain: cramping or discomfort. - Taste disturbance: altered perception of flavors. - Rash: mild skin irritation or erythema.

Serious or Rare Side Effects: - Ototoxicity: hearing loss or balance disturbances, especially with prolonged use. - Nephrotoxicity: impaired kidney function, indicated by rising serum creatinine. - Severe allergic reaction: anaphylaxis, angioedema, or bronchospasm. - Clostridioides difficile infection: severe colitis following disruption of normal flora. - Persistent vomiting: leading to dehydration. - Hematologic abnormalities: rare blood cell count changes.

Before prescribing Neomicina Labesfal, clinicians should consider patient‑specific factors and monitor for potential complications.

Renal impairment: assess kidney function and adjust therapy as needed. Hearing loss risk: avoid in patients with pre‑existing ototoxicity or concurrent ototoxic drugs. Pregnancy: use only when benefits outweigh potential fetal risks. Allergy: discontinue immediately if hypersensitivity signs appear. Drug interactions: review concomitant nephrotoxic or ototoxic agents. Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Neomicina Labesfal can interact with other medicines, altering safety or efficacy.

Major Interactions (Avoid): - Aminoglycoside antibiotics (e.g., gentamicin): additive nephrotoxicity and ototoxicity. - Loop diuretics (e.g., furosemide): increased risk of ototoxic effects. - NSAIDs (e.g., ibuprofen): heightened potential for renal impairment.

Moderate Interactions (Monitor Closely): - Vancomycin: combined risk of kidney injury. - Cyclosporine: may amplify nephrotoxic effects. - Radiographic contrast media: monitor renal function during concurrent use.